International Journal of Medical and Health Research
ISSN: 3078-4824
DOI: https://doi.org/10.61424/ijmhr.v4i3.928
Journal Homepage: https://bluemarkpublishers.com/index.php/IJMHR

IJMHR
BLUEMARK PUBLISHERS

| RESEARCH ARTICLE

MDR in Practice: Ensuring Compliance in a Rapidly Evolving Regulatory Landscape

Chrysoula I. Liakou[1] ✉ Marios Papadakis[2] and Markos Plytas[3]
[1]Chief Executive Officer, LK Connect LLC. 30N Gould St. Sheridan - WY 82801. USA
[2]Department of Surgery II. University of Witten-Herdecke. Wuppertal, Germany
[3]Academic Director. Epsilon College. Athens, Greece
Corresponding Author: Chrysoula I. Liakou, **E-mail**: mail@cliakou.gr

| ABSTRACT
The European Medical Device Regulation (EU MDR) has undergone significant reforms by mandating enhanced rigorous standards and continuous monitoring for clinical evaluation, post-market surveillance, quality management and lifecycle conformance. This paper looks to review the practical application of the MDR in a fast-changing regulatory landscape which is rife with technological innovation, digitalization, and rising patient safety expectations. A qualitative narrative literature review was used to collate available evidence for regulatory progression, clinical justification criteria, operational challenges, global harmonization, and digital-health related issues such as emerging trends associated with AI, IoT and cyber security. The review concludes that though the EU MDR engenders sustainability, transparency and quality, adoption has expanded a mandatory pre-market requirement to an organization-wide structure. It also concludes the importance of global harmonization and technology-centric regulation to drive innovation without compromising safety is crucial for sustainable progress.

| KEYWORDS

European Medical Device Regulation (EU MDR); Medical device compliance; Medical device clinical assessment; Regulatory affairs; Post-market surveillance; Quality management; Regulatory harmonization; Patient safety

| ARTICLE INFORMATION

ACCEPTED: 27 May 2026 **PUBLISHED:** 05 July 2026 **DOI:** https://doi.org/10.61424/ijmhr.v4i3.928

1. Introduction

The medical device industry is at an unprecedented time of regulatory change due to fast paced technological advances, increased complexity of products, healthcare service globalisation and increasing patient safety expectations. Medical devices have moved from traditional mechanical instruments to highly complex, embedded software and hardware platforms that incorporate artificial intelligence (AI), digital health technology, real-world data and integrated healthcare system platforms. Although these innovations have supported increased innovation and improved healthcare services provided, they have also revealed some restrictions of the effective application of classical regulations pathways, which were developed for simpler technologies. As a result, the regulators around the world have adopted a more 'robust and risk-based' system of regulations, to facilitate safeguard and accountability across the life cycle of medical devices and their associated innovative technology (Hayhurst, 2018; Goebel et al., 2023; Blom, 2024).

Within these regulatory changes is the industry-wide relatively recent overhaul of medical device governance, under the European Medical Device Regulation (EU MDR 2017/745). The EU MDR heralds a far more substantial escalation in standards and requirements across all facets of medical device governance including clinical evaluation, post-

market surveillance, technical documentation, traceability, quality management systems and regulatory responsibility as compared with the previous Medical Device Directive (MDD). The EU MDR advocates for a paradigm shift away from setting the goal of market approval at the end-point of regulatory regulation, to an active approach of generating ongoing evidence and managing lifecycle compliance, so as to maintain a standard of safety and clinical performance for medical devices throughout real-world application (Mc Dermott & Kearney, 2025; Allison, 2024). Similar industry Gupte et al., 2025) regulatory innovations in other regions display a global trend towards entrenched surveillance for the medical device industry and accelerated innovation in medical device technology.

Although these new regulations may facilitate compliance, they have made meeting and maintaining it more difficult for manufacturers and organizations involved (Han et al., 2024; Sharma et al., 2023). The contemporary environment requires organizations to simultaneously adapt to new regulatory expectations, rapidly evolving technological innovations, combined with AI and digital health integration, cybersecurity concerns, regulation of combination products, and the shifting landscape of clinical evidence requirements that is now augmented by real-world data, turning the need for compliance into a constant organizational activity.

This past research has provided cross-sectional understanding of selected individual aspects of this dynamic regulatory environment. For example, some up to date research evaluated changes in clinical assessment requirements due to the MDR, utilization of accelerated regulatory pathways, international harmonization of regulatory standards, cybersecurity regulations, regulation of digital health, and user experience during MDR implementation (McDermott & Kearney, 2025; Rimpi, et al., 2025; Chiku, et al., 2024; Dramburg, 2025). Other studies investigated open innovation in medical device development, regulatory bureaucratic complexity, real-world data, quality management in health care, and future regulatory considerations regarding emerging technologies (Shivakumar, 2025; Han et al., 2024; Knott et al., 2026). While those works have substantially contributed to the knowledge of specific topics within this regulatory domain, they have failed to explore the synergies and interactions of the combined regulatory parameters.

This fragmentation remains a significant knowledge gap. As regulatory expectations grow even broader during ongoing technological advances, organizations need harmonized compliance capabilities across all of these requirements: clinical assessment, quality systems, post-market surveillance, cybersecurity measures, governing practices in digital health, ethical frameworks, and international harmonization. Without a synthesized understanding of all of these complex needs, it is difficult for device manufacturers, regulatory experts, and policy makers to regulate digitally-enabled products and services in a pragmatic, streamlined manner that enables innovation while minimizing regulatory burden. Considering how significant these needs are today for digital health, this regulatory knowledge gap will be more crucial still for the next generation of AI-enabled medtech, Internet of Bodies (IoB) devices and systems, next-gen diagnostic methods, and digital health tools (Lu et al., 2024; Marinescu et al., 2025; Patil & Karobari, 2024).

Hence, the main aim of this study is to explore how the European MDD has been and is being implemented in the complex machinery of today's fast moving regulatory framework. On a comprehensive review of current evidences on the regulatory development, clinical evaluation processes, compliance issues, international harmonization endeavors, regulation of digital health, governance over cybersecurity, and other emerging regulatory trends on medical devices development and commercialization, this review will be the first to consolidated all the different facets of the current MDR to show a holistic picture of its current compliance status and to provide evidence based insights to enhance to a more informed regulatory decision-making process, organizations' compliance strategy and policy developments with the ultimate aim of safeguarding the benefits to the patients and ensuring sustainable health care innovation.

2. Literature Review

2.1 Evolution of the Medical Device Regulatory Landscape

The regulation of medical devices over the last 20 years has changed significantly as a reflection of technological development, globalization, and the rising nature of concern over patient safety. The early regulatory environments focused predominantly on the pre-market assessment of conformity and subsequent product approval, with less

focus on the need for continuous clinical assessment and real-world effectiveness of a medical device (Hayhurst, 2018). As newer, more elaborate forms of medical technology have arisen, from embedded software applications, to devised combinations and networks of connected healthcare it technology, the differences in the past model of regulation and the comprehensive nature required to account for the real-time, real-world performance of modern health technology have become markedly apparent (Goebel et al., 2023).

A more recent move in this change has been the introduction of the European Medical Device Regulation (EU MDR 2017/745). Compared to the previous Medical Device Directive, under the new regulation, there are increased requirements for clinical evidence and data, technical documentation, quality management systems, post-market surveillance, unique device identification, and lifecycle risk management. This move away from pre-market approval is part of a new regulatory philosophy that stresses the ongoing demonstration of safety and clinical performance throughout the development lifecycle of the device (Mc Dermott & Kearney, 2025; Allison, 2024). Similar changes globally have been implemented as regulatory bodies attempt to adapt more transparent and risk-based systems that are patient-focused to provide a platform on which to introduce innovative healthcare technologies (Gupte et al., 2025).

Simultaneously, as the prominence of the medical device sector expands globally, international harmonization of regulations has become a crucial goal for regulators. Since specific technical standards and approval processes vary among jurisdictions, manufacturers are compelled to adapt their products to diverse regulatory requirements. Such variations create burdensome compliance procedures and require prolonged development periods and increased regulatory expenditures, prompting regulators and policies developers to direct efforts toward the international harmonization of regulatory principles without encroaching on the decision-making authority of individual nations, as such convergence would further benefits in terms of innovation, marketability, and patient safety (Rimpi et al., 2025; Blom, 2024).

However, each technological innovation brings new regulatory challenges the regulatory landscape is constantly adapting to evolve with, and in response to, innovative new technologies digital health platforms, AI/ML, SaMDs, Internet-connected healthcare devices, and more. Modern regulation around medical devices has become a flexible, integrated procedure of stringent forward-looking compliance, monitoring over the entire product lifecycle, and evidence-based evidence-based regulatory determinations to promote innovation and safeguard public health (Han et al., 2024; Dramburg, 2025).

2.2 Clinical Evaluation and Evidence Requirements under the EU MDR

A key overhaul introduced by the new regulation was to tighten clinical evaluation requirements along the entire life cycle of the medical device. This involved a step away from the dilution of regulatory standards achieved by the latter approach, assuming safety and efficacy could be proved through demonstrate of substantial equivalence for each device. Instead the clinical evaluation was turned into an on-going process and a renewed focus on the collection of data from use before and after a device is given market approval (Mc Dermott & Kearney, 2025; Allison, 2024).

As a result of the rising demand for rigorous clinical evidence, the creation of regulatory plans and product development has been deeply impacted. Now, manufacturers are required to be incorporating clinical evaluation across the entire lifecycle of a device, from early risk analysis to post-market surveillance and periodic safety updates, allowing regulators to oversee the performance of devices constantly and to identify early any potential safety issues. Besides, the increasing reliance of real world data has had a positive impact on clinical evaluation, helping to bolster the evidence around long-term efficacy, clinical success, and patient attitude (Baumfeld Andre et al., 2022; Mc Dermott & Kearney, 2025).

While these advancements to the regulatory framework are in place, it poses significant challenges on the manufacturer to fulfill these increased clinical evidence requirements. Small and medium-sized manufacturers would be most affected given their limitations of financial and technical resources and handle their marketing and manufacturing costs is further increased by the extensive clinical assessments, documentation, and ongoing post-market data- gathering. Moreover, the burgeoning technology opportunities such as clinical evaluation

methodology requirements for software-driven medical devices and combination products add further challenges spanning beyond traditional regulatory approach.

The evolution of this clinical assessment paradigm can be understood in the context of new international initiatives in evidence-based regulation to improve regulatory decisions. Recognizing that regular collection of clinical evidence enhances transparency, enables effective risk management, and increases public trust in medical device technology, growing numbers of regulators now emphasize that clinical evaluation cannot consider in isolation of post-market surveillance and real-world evidence in achieving the underlying aims of the MDR (Rimpi et al., 2025; Gupte et al., 2025).

2.3 Compliance Challenges in Medical Device Development

Adoption of the European Medical Device Regulation (EU MDR) has introduced considerable challenges to the regulatory compliance during the entire lifecycle of medical device development. Apart from assuring the product quality and patient safety, application of a tighter regulation has made more meticulous demands on the clinical evidence, technical documentation, quality management systems, risk management and post-market surveillance. Regulatory adherence has shifted from a one-off activity to an organization wide obligation which necessitates perpetual regulatory management, collaborative efforts and lifecycle control (Han et al., 2024; Mc Dermott & Kearney, 2025).

One of the leading compliance issues is essentially constraints imposed by regulatory requirements at the same time as need for fast paced innovation. Medical device manufacturers have to ably meet the steadily increasing regulatory demands with fast paced technological changes and competitive market pressures. The same issue is particularly visible during the use of novel medical technologies during the course of this project, wherein the increasing pace of regulatory requirements caused delays in the development and approval of new products, increased the product cost, and postponed time-to-market. As a result product design must account for regulatory planning at the earliest stages so that the risks of non-compliance are minimized and the products are brought to market quickly (Shivakumar, 2025; Gupte et al., 2025).

The increased complexity of medical devices also increased compliance burdens. As medical devices include more software, more digital interfaces, more combination products and interconnected healthcare systems, manufacturers are required to follow several regulatory areas at once including clinical evaluation, software validation, quality, usability, engineering and risk management. As these requirements overlap across teams, there is a greater need for increased collaboration across engineering, clinical, regulatory and quality management teams who can ensure not only compliance across the lifecycle but not the separate regulatory process (Goebel et al., 2023; Gupta et al., 2024).

Organizational readiness is crucial as well in assuring the successful implementation of MDR. The continued reliance on internal sources of regulatory expertise and the need to adapt existing quality systems to new requirements has proved daunting to many manufacturers who struggle with the interpretation of new regulatory guidance. Such constraints tend to be more significant in smaller and medium size businesses where financial, technical and human resources are likely to be in short supply to undertake the regulatory functions. As the regulatory landscape continues to change, investing in regulator skills/competencies, investing in internal governance and fostering of continued professional development has become the way forward to ensure long term compliance (Sharma et.al, 2023; Blom, 2024)

Figure 1. MDR Compliance Framework



The literature points to the fact that successful MDR compliance demands a proactive, integrated regulatory approach that is spanning the entire medical device development process. Instead of compliance being simply a regulator mandated activity to be conducted in the lead up to product approval, manufacturers need to incorporate a simple "compliance as usual" approach across all aspects of medical device development including clinical evidence, quality management, risk management, regulatory intelligence and post market surveillance and experience.

Table 1. Regulatory Changes Introduced by EU MDR

Regulatory Area	Previous Approach	MDR Approach
Clinical evidence	Limited	Extensive lifecycle evidence
Risk management	Pre-market emphasis	Continuous lifecycle management
Technical documentation	Moderate	Comprehensive documentation
Post-market surveillance	Limited	Mandatory continuous surveillance
Traceability	Basic	Unique Device Identification (UDI)

2.4 Global Regulatory Harmonization and International Perspectives

That an industry, such as the medical device industry, is becoming increasingly globalized has led to the larger need and desire for increased regulatory harmonization between regions. Healthcare providers in different parts of the world sometimes work with the same medical device manufacturers, each of which develop products for many countries with their own specific regulatory requirements, conformity assessment procedures and documentation standards. Existing regulations may serve to protect health, but from a regulatory perspective, differences in regulatory expectations too often offer little benefit to healthcare providers while leading to redundant testing and develop in expensive medical device programs with greater costs to developers and time-to-market for devices. Thus, international regulatory convergence has been identified as a complex solution to the issues of regulatory efficiency and global healthcare provision (Rimpi et al., 2025 Gupte et al., 2025).

Recently, harmonization efforts have also focused on universally adopted regulatory principles, instead of harmonizing national legislation to a standard. Current regulatory environments tend to favor a universally adopted set of medical device principles that include a risk-based classification, evidence-based clinical assessment, quality management systems, surveillance throughout the device lifecycle, and open and transparent regulatory decision-making. These principles are adopted differently by various regulatory authorities, but enable regulators to achieve greater similarity in their regulatory practices while responding to specific healthcare and legal needs of countries (Goebel et al., 2023; Sharma et al., 2023).

Comparable trials in different LMIC health system contexts highlight that establishing the legal framework alone is insufficient for successful regulation of medical device markets; physical infrastructure, stakeholder involvement, and capacity strengthening are necessary to any successful MDR implementation process and to ensure the intended benefits of the regulatory changes (Chiku et al., 2024; Blom, 2024). How they intermight vary by regulatory framework and the resources available to the regulator.

Even with sustained progress toward international convergence, total regulatory harmonization is difficult with differences in legal frameworks, healthcare systems, and national regulatory policies. Increasing use of expanded approval programs, changing requirements for clinical evidence, and different country specific markets prior to individual product market entrances all continue to impact manufacturers' development of global regulatory strategies. As such, flexible regulatory planning approaches should be develop that can be achieved across multiple regulatory frameworks, while consistently meeting global standards for product quality, safety, and clinical performance. International regulatory collaboration and dialogue will likely also need to be enhanced to reduce compliance burden, support innovation, and advance equitable access to safe and effective medical devices worldwide (Gupte et al., 2025; Aimer & Baldridge, 2026).

2.5 Digital Health, Artificial Intelligence, Cybersecurity, and Emerging Regulatory Issues

The emergence of new digital health technology, artificial intelligence (AI), connected devices, and the rise of digital health early and often has driven a fundamental shift in medical device regulation. This is evidenced by the exponential growth of software-based and AI-enabled devices that leverage cloud-based software platforms, interpretable deep learning and broad healthcare connectivity markets that are continuously capturing and sharing clinical information. While this has opened the door to acceleration of diagnostics, personalized medicine and efficient approaches to care delivery, it also challenges the current regulatory paradigm in ways that were not

originally conceived to ensuring quality and safety, demanding the regulator to develop new continuous adaptive governance (Dramburg, 2025; Patil & Karobari, 2024).

Over the last decade, artificial intelligence has become one of the most disruptive growing technologies impacting medical device innovation and regulation and AI-enabled medical devices are capable of learning from clinical data, assisting in diagnostic decision-making, and updating themselves with new algorithms. As a result, the flexible nature of these intelligent devices poses additional challenges to traditional regulatory and submission pathways, which have been established more for static devices. Addressing algorithm transparency, validation, clinical reliability, and performance maintenance has therefore become a requirement for regulatory compliance through risk mitigation and gaining public trust in AI-assisted medical technologies (Patil & Karobari, 2024; Knott et al., 2026).

In parallel with AI, cybersecurity has also become a key facet of regulatory oversight of medical devices. As medical devices are connected more and more to other hospital systems, there are increased opportunities for cybersecurity risks to occur whether through hacking, data theft, malware infiltration, or directly tampering with the device hardware or software which could, for instance, compromise critical clinical bedside functions. As such, cybersecurity governance has now become a key regulatory priority, with manufacturers now obligated to implement certain security controls throughout the entire lifecycle of the device from product development and risk management to post-market updates and software maintenance (Biasin & Kamenjasevic, 2020).

Figure 2. Challenges Affecting MDR Compliance



Emerging examples of these trends include the adoption of Internet of Bodies systems, leveraging more advanced microelectromechanical systems (MEMS), BioMEMS, and data-centric healthcare services that utilize ubiquitous sensors, fitbit-type devices and other personal health systems that provide rich patient data streams. As these clinical technologies increase their adoption in practice, more attention will be required in regulatory systems toward clarifying issues of interoperability, data governance, validation of software/algorithms, ethics concerns around handling Patient data, ongoing lifecycle management of systems, etc. Hence, future regulatory systems will need a much higher degree of flexibility to accommodate these evolving areas of technology (Marinescu et al., 2025; Baumfeld Andre et al., 2022).

2.6 Future Directions for MDR Compliance

Medical device technologies will continue to develop and evolve, and it is likely that EU MDR compliance will tend to require use of adaptive, evidence based, technology driven regulatory approaches in the future. As medical devices evolve to become more intelligent, networked, and integrated with software, the current approaches to compliance involving primarily pre-market approval will not be sufficient. Moving forward, compliance approaches

are expected to be more focused on the lifecycle of the device and to include clinical evaluation, post-market data, real-world evidence, and proactive risk management to maintain safe and functional devices over the course of their life cycle (Mc Dermott & Kearney, 2025; Aimer & Baldridge, 2026).

Another priority for future MDR compliance is global regulatory harmonization efforts. While enhancements in implementing common regulatory principles among jurisdictions have been achieved, divergence in clinical evidence standards, conformity assessment rules, and pathways to market access might still pose obstacles for global manufacturers. Enhanced cooperation between regulatory agencies and adoption of more harmonized regulatory standards may lead to a reduction of unwarranted duplication, balanced regulatory efficiency, and a faster introduction of new medical devices to the patients, while maintaining safety and quality standards (Rimpi et al., 2025; Gupte et al., 2025).

Digital transformation will also be inherent to future compliance strategies. The use of artificial intelligence, digital health platforms, automation and large language models in regulatory affairs will provide opportunities to optimize documentation management, regulatory intelligence, quality assurance and compliance monitoring. These tools could reinforce organization effectiveness by automating repetitive regulatory activities, supporting decision making and providing timely answers to new regulatory obligations. The adoption, however, has to be properly validated, transparent and governed so to sustain regulatory integrity and stakeholder trust (Knott et al., 2026; Patil & Karobari, 2024).

3. Methodology

A qualitative narrative literature review was used in this research to explore how the EU MDR is practically implemented in an ever-evolving global regulatory landscape. A thematic synthesis was applied to synthesize the current academic evidence on regulatory adherence, clinical evidence requirements, regulatory convergence, digital health governance, cybersecurity, and the ongoing issues altering regulation in medical device development. This was a suitable method in the context of this research as it allows the critical analysis of evidence from multiple disciplines, the identification of basic themes of the current and future regulatory environment.

The review has been structured around the overarching purpose of systematically reviewing the impact of the MDR on compliance practices throughout the lifecycle of a medical device. In order to address this purpose, the published literature has been subgrouped into 6 areas: the changing landscape of medical device regulation, clinical evaluation and evidence requirements, complying with medical device development, worldwide regulatory harmonisation, new regulatory challenges with digital health technologies and the future of MDR compliance. This thematic organization of the literature has enabled a seamless synthesis of the key regulatory advances and potential consequences.

The literature included in the review was decided solely on the chosen textbooks for this project. The literature reviewed by the searches involved peer reviewed journals articles, book chapters, doctoral dissertations, conference contributions and recognized academic literature dealing with modern regulation issues of medical device. No other references were utilized to achieve uniformity in methodology or stay true to the evidence base.

A thematic analytical method was employed in the synthesis of the literature. The major focus of each publication with regards to MDRa s implementation and regulatory adherence was extracted and then related concepts were categorized under common themes to facilitate a critical appraisal of areas of consensus and inconsistency in the literature. In the thematic review, instead of reporting findings of each publication separately, findings from various papers were coherently aggregated to highlight current regulatory trends, pinpoint implementation issues and spotlight potential regulatory solutions.

In order to build on analytical rigor, new efforts were made to synthesize evidence between multiple regulatory viewpoints and prevent reiteration of findings and summative descriptions of individual articles. Special focus was placed on recurring regulatory challenges in areas such as clinical evidence generation, lifecycle compliance, regulatory harmonization, digital transformation, cybersecurity and organizational preparedness. This analytical framework provided a means to synthesize present understanding of MDR implementation and to bolster evidence-based forecasts of future regulatory compliance amidst a more digital healthcare industry.

4. Results

The thematic synthesis of the literature reviewed demonstrated the global progressive integration and "more complete" nature of compliance with the EU MDR regulation beyond registration, toward ongoing clinical assessment, lifecycle risk management, post-market surveillance, digital governance, and organization quality management. Five overarching themes were identified: (i) regulatory reform, (ii) advanced clinical registration and lifecycle competencies, (iii) the implementation and organizational hurdles, (iv) the worldwide alignment of regulatory influence, and (v) the newly developing digital and technological compliance imperatives. As a result, it can be concluded that MDR implementation will be truly successful when higher-level, overarching compliance principles integrate and resemble one another in the face of novel, rising technical clinical standards and regulations.

Table 2. Major Themes Emerging from the Reviewed Literature

Theme	Key Findings	Representative References
Regulatory transformation	MDR has shifted regulatory oversight from pre-market approval toward lifecycle-based compliance emphasizing safety, performance, and continuous surveillance.	McDermott & Kearney (2025); Allison (2024); Blom (2024)
Clinical evaluation and evidence generation	Stronger clinical evidence, post-market surveillance, and real-world data have become central to regulatory decision-making.	McDermott & Kearney (2025); Baumfeld Andre et al. (2022); Gupte et al. (2025)
Compliance and organizational challenges	Manufacturers face increased documentation, regulatory complexity, resource demands, and multidisciplinary coordination.	Han et al. (2024); Shivakumar (2025); Sharma et al. (2023)
Global harmonization	International collaboration seeks greater consistency in regulatory requirements while maintaining patient safety and innovation.	Rimpi et al. (2025); Chiku et al. (2024); Aimer & Baldridge (2026)
Digital health and emerging technologies	AI, cybersecurity, digital health, and connected medical devices require adaptive regulatory frameworks and continuous governance.	Biasin & Kamenjasevic (2020); Dramburg (2025); Knott et al. (2026); Marinescu et al. (2025)

Within the review, the dominant theme rests in the 'regulatory change' trends illustrated. It is clear that the introduction of the MDR has had a radical impact on regulatory compliance, with the focus moving away from initial market approval, towards lifelong adherence to the device. This has resulted in the increased regulation, driven through greater clinical assessment requirements, heightened post-market surveillance, increased traceability and the accountability of the manufacturer. It can be inferred from the literature that compliance is evolving into an ongoing quality management process, rather than an autonomous regulatory requirement (McDermott and Kearney, 2025; Alliston, 2024).

An additional notable emerging trend is the expanding role of clinical data in regulatory decisions. Across the literature reviewed, there was a consensus that manufacturers were expected to develop a sufficient body of clinical evidence prior to market approval, and to continue the conduct of evidentiary studies in the post-market setting to demonstrate the safety and clinical performance of medical devices. The use of real-world data has enhanced evidence-based regulation by allowing regulators to monitor long-term device effectiveness and emerging safety signals over the course of the device lifecycle. This development highlights the growing prominence of ongoing evidence generation in ensuring healthcare security (Baumfeld Andre et al., 2022 Gupte et al., 2025).

An aspect of the eight direct effects was that regulatory compliance became significantly more burdensome. Companies needed to meet the higher standards for technical documentation, quality management, clinical investigations, risk management and regulatory reporting. The additional requirements created a higher burden for companies, especially small and medium manufacturers that lack substantial regulatory resources and expertise, and the successful achievement of them presumed forward looking regulatory planning, organization and

partnerships early in product development, integrating engineering, clinical, regulatory and QA. teams (Han et al. 2024; Shivakumar, 2025).

Another major discovery was international harmonization. Despite regulators still working within largely diverse legislative frameworks, they are heading toward more harmonized regulator (International Harmonization), policies focused on evidence-based regulation, lifecycle data gathering, risk-based management and product safety with fragmented practice procedures including conformity assessment and the approval process. The need to conduct simultaneous endorsement global market was hampered by variation in different counties implementation and rejection process. Literature showed the need to work closely globally and to jointly reduce intervention fragmented practice along with compelling reg ulatory and Good Medical Practice (Rimpi et al., 2025; Chiku et al., 2024).

The types of dynamic interactions between regulator and manufacturer as well as the pace of technological progress has catalyzed the development of compliant as a continually applied organizational capacity that both allows regulated innovation but also regards public health interests. These summarized evidence form the basis of the following discussion that explores their possible consequences for the regulation of the policy, the manufacturer, and the future of MDR compliance.

5. Discussion

The results of this review show clearly that the implementation of the European Medical Device Regulation, EU MDR, has heralded not only a fundamental paradigm shift in regulatory compliance, but has also transformed the regulatory system from pre-market approval affair to a comprehensive lifecycle management program. Illustratively, the older regulatory framework was mainly focused on the pre-market approval, whereas the current system mandates ongoing clinical assessments, post-market surveillance, technical documentation, active risks management, and many other activities occurring all through device lifecycle. Evidently, this shift in paradigm has significantly bolstered the control over medical devices and can be seen as a major step for the benefit of patient safety and improved liability for manufacturers. This kind of paradigm shift can help establish medical device regulation as a mutual drive for quality and compliance as an extended quality assurance framework, rather than a standalone regulatory target for compliance (Mc Dermott & Kearney, 2025; Allison, 2024).

One major issue that was highlighted by the literature review was the expansion of evidence-based regulatory decision making. With the more stringent clinical evaluation requirements imposed under the MDR, manufacturers will need to able to demonstrate strong scientific evidence prior to the devices entering the market (through the pre-market phase); and continuously update this evidence with data from post-market surveillance and from clinical practice. Such changes have augmented regulatory confidence of device performance in a real world setting over pre-market investigations, and the continued reliance on real-world evidence will also allow, for example, earlier detection of safety signals, and growth of regulatory intervention options through the product life-cycle (Baumfeld Andre et al., 2022; Mc Dermott & Kearney, 2025).

Besides the regulatory advantages, the evidence also suggests that MDR imposes considerable operational burden on manufacturers. With more extensive documentation, advanced clinical investigations, rigorous regulatory scrutiny, and the heightened quality management obligations, the new regulation has brought higher economic, technical, and administrative costs to the once more accessible regulatory system. Particularly, this burden is heavier among small- and medium-sized enterprises that in general lack of experience and capacity in regulation. As a result, the regulatory planning is increasingly involved in product design, quality management, and innovation activities, which are deemed as the key to realising sustainable compliance while avoiding delays in product development and market availability (Han et al., 2024; Shivakumar, 2025; Sharma et al., 2023).

The review also highlights the fact that technological innovation is still advancing faster than regulation. The fast uptake of AI, software as a medical device, digital health platforms, linked healthcare systems and IoB technologies has brought to the forefront regulatory challenges that go beyond traditional assessment of medical devices. Cybersecurity, algorithm validation, updates to the software, interoperability, data governance and ethical management of patient data are now drivers of regulatory compliance. These innovations require oversight systems and regulations to be flexible and agile enough to keep up with a fast evolving landscape whilst ensuring the

highest levels of patient safety, transparency and clinical efficacy (Biasin & Kamenjasevic, 2020; Dramburg, 2025; Knott et al., 2026; Marinescu et al., 2025).

Additionally noteworthy is the trend toward greater global regulatory convergence. While many countries and regions have adopted these similar factors, a universally applicable set of requirements in terms of risk management, clinical evidence, lifecycle control, and quality has not been realized and can lead to avoidable burdens to world-wide market access. As more similarities are reached, reliance among regulatory authorities could minimize duplications in activities, standardize conformity assessment processes, and facilitate multi-country market access more efficiently. Therefore the existing literature indicates that international harmonization efforts should not be discounted for accelerating worldwide access to medical technologies (Rimpi et al., 2025; Gupte et al., 2025; Chiku et al., 2024).

6. Conclusion

The European Medical Device Regulation (EU MDR) has changed the rules for medical device compliance, separating away from a pre-market focus to a life-cycle approach based on clinical safety data, risk management, quality assurance practices and post-market surveillance. This has added extra criteria to enhance the safety of patients and responsibilities of regulators while also increasing the requirements of the manufacturer in terms of compliance.

This review illustrates what it takes to attain successful MDR compliance within an integrated organizational model, which encompasses strong clinical evidence and planning, cross-discipline collaboration, and ongoing surveillance through the product's lifecycle while offering a glimpse at what is rapidly evolving through future technologies, including AI, digital health, and connected medical devices.

In general, the interface between regulatory requirements and innovation will be instrumental to every effort to attain sustainable MDR compliance. Further improvements in international regulatory convergence, robust evidence-based decision-making, and flexible approaches to compliance will all be necessary to foster safe and effective yet innovative medical devices in a rapidly changing, borderless marketplace. Future research should delve deeper into the nuances of the practical application of requirements and the impact of the evolving regulatory environment on innovation over time.

Funding: This research received no external funding

Conflicts of Interest: The authors declare no conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Artificial Intelligence (AI) Use Disclosure: The authors declare that no artificial intelligence tools were used in the preparation of this manuscript

References

[1] Aimer, O., & Baldridge, C. (2026). *Navigating medical device safety: Current status, challenges, and future regulatory directions*. *Drug Safety, 49*(2), 163–175.

[2] Allison, R. V. (2024). *Ensuring patient safety: Navigating EU MDR compliance and global policy in healthcare* (Doctoral dissertation, University of Pittsburgh).

[3] Atsaves, V., Lekakis, L., Feretzaki, M., Leventaki, V., Liakou, C., Drakos, E., et al. (2009). JunB oncogenic activity in anaplastic large cell lymphoma. *Laboratory Investigation, 89*, 254A.

[4] Baumfeld Andre, E., Carrington, N., Siami, F. S., Hiatt, J. C., McWilliams, C., Hiller, C., ... & Schulz, W. L. (2022). The current landscape and emerging applications for real-world data in diagnostics and clinical decision support and its impact on regulatory decision making. *Clinical Pharmacology & Therapeutics, 112*(6), 1172–1182.

[5] Biasin, E., & Kamenjasevic, E. (2020). *Cybersecurity of medical devices: Regulatory challenges in the EU*.

[6] Blom, P. (2024). *Assessing the present and future regulatory landscape governing medical devices from the perspective of the Finnish Health Authority*.

[7] Chiku, C., Maruta, T., Mbiba, F., & Manasa, J. (2024). Navigating regulatory landscape: A qualitative exploration of medical devices and in vitro diagnostic medical devices oversight in Zimbabwe through key stakeholder perspectives. *PLOS ONE, 19*(5), e0287415.

[8] Dramburg, S. (2025). Legal and regulatory challenges for digital health technologies with a focus on the European legal situation. In *Digital Allergology: From Theory to Practice* (pp. 39–47). Springer Nature Switzerland.
[9] Elshikh, M. S., Alwahibi, M. S., Alexiou, A., Papadakis, M., et al. (2024). Soil pollution: An agricultural and environmental problem with nanotechnological remediation opportunities and challenges. *Discover*. Springer.
[10] Gkagkaris, L., Papadakis, M., et al. (2022). The revolutionary Gustav Adolf Neuber: A tribute to the father of aseptic surgery. *Surgical*. Sage Journals.
[11] Goebel, S., Verna, V., Marty, C., & Neadle, S. W. (2023). General overview of global combination product regulatory landscape. In *The Combination Products Handbook* (pp. 441–504).
[12] Gogali, F., Paterakis, G., Rasidakis, G., Kaltsas, G., Gousis, P., Neonakis, E., et al. (2011). T regulatory lymphocytes (Tregs) and NK cell interaction in thyroid papillary cancer (PTC): Immunotherapy perspectives. *Basic & Clinical Pharmacology & Toxicology, 109*, 29.
[13] Gupta, D. K., Tiwari, A., Yadav, Y., Soni, P., & Joshi, M. (2024). Ensuring safety and efficacy in combination products: Regulatory challenges and best practices. *Frontiers in Medical Technology, 6*, 1377443.
[14] Gupte, T., Nitave, T., & Gobburu, J. (2025). Regulatory landscape of accelerated approval pathways for medical devices in the United States and the European Union. *Frontiers in Medical Technology, 7*, 1586070.
[15] Han, Y., Ceross, A., & Bergmann, J. (2024). More than red tape: Exploring complexity in medical device regulatory affairs. *Frontiers in Medicine, 11*, 1415319.
[16] Hayhurst, C. (2018). The quest for quality: Navigating the changing landscape of healthcare technology regulations. *Biomedical Instrumentation & Technology, 52*(3), 182–191.
[17] Josephs-Spaulding, J., & Singh, O. V. (2021). Medical device sterilization and reprocessing in the era of multidrug-resistant (MDR) bacteria: Issues and regulatory concepts. *Frontiers in Medical Technology, 2*, 587352.
[18] Kitonakis, N., & Kontis, A. (2008). The determinants of Greek foreign direct investments in Southeast European countries. *Southeast European and Black Sea Studies*.
[19] Knott, M., Krebs, M., & Kerscher, A. (2026). Large language models in healthcare quality management: A European perspective on process automation and compliance. *Frontiers in Digital Health, 8*, 1761641.
[20] Liakou, A. I., Arabatzi, K., Liakou, C. I., & Theodorakis, M. J. (2008). Impact of obesity on cytokine secretion patterns following an oral glucose tolerance test in individuals with normal glucose tolerance. *Review of Clinical Pharmacology and Pharmacokinetics – International Edition*.
[21] Liakou, A. I., Liakou, C. I., & Zouboulis, C. C. (2012). Acne and nutrition. In *Handbook of Diet, Nutrition and the Skin* (pp. 413–422).
[22] Liakou, C. I., Papadakis, M., & Plytas, M. (2025). The challenges for manufacturers of the increased clinical evaluation requirements under the European Union medical device regulations. *International Journal of Engineering Technology and Research Management, 9*(3), 32–40.
[23] Liakou, C. I., Papadakis, M., & Plytas, M. (2025). Clinical evaluation of immunotherapy vaccines as medical devices: Regulatory challenges and assessment strategies. *International Journal of Engineering Technology and Research Management, 9*(3), 32–31.
[24] Liakou, C. I., & Plytas, M. (2025). Patient access to high-risk devices for unmet medical needs. *International Journal of Engineering Technology and Research Management, 9*(3), 41–46.
[25] Lu, H., Alhaskawi, A., Dong, Y., Zou, X., Zhou, H., Ezzi, S. H. A., et al. (2024). Patient autonomy in medical education: Navigating ethical challenges in the age of artificial intelligence. *INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 61*, 00469580241266364.
[26] Marinescu, M. R., Ionescu, O. N., Pachiu, C. I., Dinescu, M. A., Muller, R., & Șuchea, M. P. (2025). Next-gen healthcare devices: Evolution of MEMS and BioMEMS in the era of the Internet of Bodies for personalized medicine. *Micromachines, 16*(10), 1182.
[27] McDermott, O., & Kearney, B. (2025). A review of the literature on the new European Medical Device Regulations requirements for increased clinical evaluation. *International Journal of Pharmaceutical and Healthcare Marketing, 19*(1), 1–21.
[28] Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024). An overview of the recent advances in antimicrobial resistance. *Microorganisms, 12*(9), 1920.
[29] Papadakis, M., Rahmanian-Schwarz, A., et al. (2017). Negative-pressure wound therapy and early pedicle flap reconstruction of the chest wall after epirubicin extravasation. *The Journal of*.
[30] Patil, S. R., & Karobari, M. I. (2024). Exploring artificial intelligence for enhanced endodontic practice: Applications, challenges, and future directions. *Advances in Public Health, 2024*(1), 8075515.
[31] Rimpi, Verma, S. J., Pinky, & Baldi, A. (2025). Evidence-based recommendations for comprehensive regulatory guidelines in medical devices: The imperative for global harmonization. *Naunyn-Schmiedeberg's Archives of Pharmacology, 398*(7), 7697–7711.
[32] Saboor, M., Haque, S., Farhana, A., Papadakis, M., et al. (2024). Natural products in the management of neurodegenerative diseases. *Nutrition &*. Springer.

[33] Sharma, B., Gurung, A., Pradhan, P., Darjee, D., & Kotla, N. K. (2023). Navigating the regulatory landscape: Key trends shaping today's regulatory affairs environment. *International Journal of Drug Regulatory Affairs, 11*(4), 87–92.
[34] Sharma, P., Liakou, C., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., et al. (2008). CTLA-4 blockade increases interferon-gamma-producing CD4(+) ICOS(HI) cells to shift the ratio of effector to regulatory T cells in cancer patients. *Journal of Immunotherapy, 31*(9), 960.
[35] Sharma, P., Liakou, C., Kamat, A., Chen, H., Ng Tang, D., Sun, J., Troncoso, P., et al. (2008). Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting. *Cancer Immunity, 8*(Suppl. 1).
[36] Shivakumar, P. (2025). *The role of open innovation in medical device development: Challenges of navigating the European regulatory landscape* (Doctoral dissertation, Kauno technologijos universitetas).
[37] Sideris, A. C., Tsakiris, S., Messari, I., Liakou, C. I., & Carageorgiou, H. (2008). Effects of rivastigmine plus selegiline [(-) deprenyl)] on brain enzymes, antioxidant status and learning performance of aged rats. *Review of Clinical Pharmacology and Pharmacokinetics – International Edition*.
[38] Sklavounos, D., Edoh, A., & Plytas, M. (2017). A statistical approach based on EWMA and CUSUM control charts for R2L intrusion detection. In *2017 Cybersecurity and Cyberforensics Conference (CCC)* (pp. 25–30).
[39] Tsagkaris, C., Papadakis, M., et al. (2023). Is it about time to develop social surgery? *American Journal of Surgery.*
[40] Tzamaria, M., Liakou, C., & Papadakis, M. (2025). CTLA-4 treatment in pancreatic cancer. *International Journal of Advanced Research in Engineering, Science & Management, 13*(3), 2826–2833.